NASDAQ:ANGO AngioDynamics - ANGO Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding AngioDynamics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $12.40 -0.02 (-0.16%) (As of 03/28/2023 12:00 AM ET) Add Compare Share Share Today's Range$12.33▼$12.6050-Day Range$11.40▼$13.5952-Week Range$11.33▼$24.87Volume151,061 shsAverage Volume332,989 shsMarket Capitalization$485.21 millionP/E RatioN/ADividend YieldN/APrice Target$28.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability AngioDynamics MarketRank™ ForecastAnalyst RatingStrong Buy4.00 Rating ScoreUpside/Downside129.8% Upside$28.50 Price TargetShort InterestHealthy2.93% of Float Sold ShortDividend StrengthN/ASustainability-0.99Upright™ Environmental ScoreNews Sentiment0.25Based on 4 Articles This WeekInsider TradingSelling Shares$59,997 Sold Last QuarterProj. Earnings Growth1,000.00%From $0.01 to $0.11 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.28 out of 5 starsMedical Sector364th out of 1,002 stocksSurgical & Medical Instruments Industry32nd out of 104 stocks 2.0 Analyst's Opinion Price Target Upside/DownsideAccording to analysts' consensus price target of $28.50, AngioDynamics has a forecasted upside of 129.8% from its current price of $12.40.Amount of Analyst CoverageAngioDynamics has only been the subject of 1 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted2.93% of the float of AngioDynamics has been sold short.Short Interest Ratio / Days to CoverAngioDynamics has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in AngioDynamics has recently decreased by 4.31%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAngioDynamics does not currently pay a dividend.Dividend GrowthAngioDynamics does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAngioDynamics has received a 59.93% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Ultrasound machines", "Clinical laser systems", and "Intravenous therapy equipment" products. See details.Environmental SustainabilityThe Environmental Impact score for AngioDynamics is -0.99. Previous Next 2.4 News and Social Media Coverage News SentimentAngioDynamics has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for AngioDynamics this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for ANGO on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows3 people have added AngioDynamics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AngioDynamics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $59,997.00 in company stock.Percentage Held by InsidersOnly 4.90% of the stock of AngioDynamics is held by insiders.Percentage Held by Institutions94.94% of the stock of AngioDynamics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for AngioDynamics are expected to grow by 1,000.00% in the coming year, from $0.01 to $0.11 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AngioDynamics is -14.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AngioDynamics is -14.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAngioDynamics has a P/B Ratio of 1.13. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About AngioDynamics (NASDAQ:ANGO) StockAngioDynamics, Inc. is a medical device company, which engages in the development, manufacture, and sale of medical devices for vascular access, surgery, peripheral vascular disease, and oncology. It offers ablation systems, fluid management systems, vascular access, angiographic, drainage. thrombolytic, and venous products. The company was founded by Eamonn P. Hobbs on February 9, 1988 and is headquartered in Latham, NY.Read More Receive ANGO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AngioDynamics and its competitors with MarketBeat's FREE daily newsletter. Email Address ANGO Stock News HeadlinesMarch 28, 2023 | americanbankingnews.comAngioDynamics (ANGO) Scheduled to Post Earnings on ThursdayMarch 26, 2023 | cnbc.comThe Street awaits key inflation report next week as banking worries persistMarch 29, 2023 | Weiss Ratings (Ad)Urgent WarningThis was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …March 20, 2023 | americanbankingnews.comAngioDynamics (NASDAQ:ANGO) Receives New Coverage from Analysts at StockNews.comMarch 18, 2023 | finance.yahoo.comShareholders in AngioDynamics (NASDAQ:ANGO) are in the red if they invested a year agoMarch 13, 2023 | finance.yahoo.comAngioDynamics to Report Fiscal 2023 Third Quarter Financial Results on March 30, 2023February 28, 2023 | finance.yahoo.comAngioDynamics to Participate in Three Investor Conferences in MarchJanuary 24, 2023 | reuters.comANGO.N - | Stock Price & Latest News | ReutersMarch 29, 2023 | Weiss Ratings (Ad)Urgent WarningThis was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …January 24, 2023 | finance.yahoo.comAre Options Traders Betting on a Big Move in AngioDynamics (ANGO) Stock?January 10, 2023 | finance.yahoo.comAngioDynamics, Inc. (NASDAQ:ANGO) Q2 2023 Earnings Call TranscriptJanuary 9, 2023 | finance.yahoo.comAngioDynamics Second Quarter 2023 Earnings: Revenues Beat Expectations, EPS LagsJanuary 7, 2023 | seekingalpha.comAngioDynamics, Inc. (ANGO) Q2 2023 Earnings Call TranscriptJanuary 6, 2023 | finance.yahoo.comAngioDynamics (ANGO) Q2 Earnings, Revenues Top EstimatesJanuary 5, 2023 | finance.yahoo.comAngioDynamics revenue jumps 9.1% as hospital staff shortages continue to impact salesJanuary 5, 2023 | msn.comEarnings Preview For AngioDynamicsJanuary 5, 2023 | apnews.comAngioDynamics: Fiscal Q2 Earnings SnapshotJanuary 5, 2023 | finance.yahoo.comAngioDynamics Reports Fiscal 2023 Second Quarter Financial Results; Reaffirms GuidanceJanuary 5, 2023 | finance.yahoo.comAngioDynamics (ANGO) Surpasses Q2 Earnings and Revenue EstimatesJanuary 5, 2023 | seekingalpha.comAngioDynamics Non-GAAP EPS of $0.01 beats by $0.02, revenue of $85.4M beats by $1.02M, reaffirms fiscal year 2023 outlookDecember 30, 2022 | finance.yahoo.comWall Street Thinks This Obscure Growth Stock Could Soar 92% in 2023December 30, 2022 | finance.yahoo.comSARTORIUS (SARTF) Surges 7.4%: Is This an Indication of Further Gains?December 22, 2022 | finance.yahoo.comAnalysts Expect Breakeven For AngioDynamics, Inc. (NASDAQ:ANGO) Before LongDecember 15, 2022 | finance.yahoo.comAngioDynamics to Report Fiscal 2023 Second Quarter Financial Results on January 5, 2023November 28, 2022 | seekingalpha.comAngioDynamics Now Finds Itself Deep In The Street's DoghouseNovember 25, 2022 | finance.yahoo.comA number of insiders bought AngioDynamics, Inc. (NASDAQ:ANGO) stock last year, which is great news for shareholdersNovember 18, 2022 | finance.yahoo.comAngioDynamics to Present at the Piper Sandler Healthcare ConferenceSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ANGO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AngioDynamics and its competitors with MarketBeat's FREE daily newsletter. Email Address ANGO Company Calendar Last Earnings1/05/2023Today3/28/2023Next Earnings (Confirmed)3/30/2023Fiscal Year End5/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNASDAQ:ANGO CUSIP03475V10 CIK1275187 Webwww.angiodynamics.com Phone(518) 795-1400Fax518-795-1401Employees800Year Founded1988Price Target and Rating Average Stock Price Forecast$28.50 High Stock Price Forecast$35.00 Low Stock Price Forecast$22.00 Forecasted Upside/Downside+129.8%Consensus RatingStrong Buy Rating Score (0-4)4.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.83) Trailing P/E RatioN/A Forward P/E Ratio1,240.00 P/E GrowthN/ANet Income$-26,550,000.00 Net Margins-9.98% Pretax Margin-10.79% Return on Equity-0.14% Return on Assets-0.10% Debt Debt-to-Equity Ratio0.12 Current Ratio2.16 Quick Ratio1.30 Sales & Book Value Annual Sales$316.22 million Price / Sales1.53 Cash Flow$0.78 per share Price / Cash Flow15.99 Book Value$10.96 per share Price / Book1.13Miscellaneous Outstanding Shares39,130,000Free Float37,216,000Market Cap$485.21 million OptionableOptionable Beta0.62 Social Links Key ExecutivesJames Christopher ClemmerPresident, Chief Executive Officer & DirectorDavid D. HelselSVP-Global Operations, Research & DevelopmentStephen A. TrowbridgeChief Financial Officer & Executive Vice PresidentKim L. SeaburySenior Vice President-Information TechnologyJuan Carlos SernaSenior VP-Scientific & Clinical AffairsKey CompetitorsOrthofix MedicalNASDAQ:OFIXAccurayNASDAQ:ARAYSurmodicsNASDAQ:SRDXCardiovascular SystemsNASDAQ:CSIIAlphatecNASDAQ:ATECView All CompetitorsInsiders & InstitutionsVictory Capital Management Inc.Bought 1,369,109 shares on 3/10/2023Ownership: 10.891%State of WyomingBought 5,294 shares on 2/16/2023Ownership: 0.017%Morgan StanleyBought 90,798 shares on 2/15/2023Ownership: 0.954%Legal & General Group PlcBought 2,626 shares on 2/15/2023Ownership: 0.246%AQR Capital Management LLCBought 36,023 shares on 2/15/2023Ownership: 0.133%View All Insider TransactionsView All Institutional Transactions ANGO Stock - Frequently Asked Questions Should I buy or sell AngioDynamics stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AngioDynamics in the last twelve months. There are currently 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "strong buy" ANGO shares. View ANGO analyst ratings or view top-rated stocks. What is AngioDynamics' stock price forecast for 2023? 1 Wall Street research analysts have issued 12 month price objectives for AngioDynamics' shares. Their ANGO share price forecasts range from $22.00 to $35.00. On average, they expect the company's stock price to reach $28.50 in the next year. This suggests a possible upside of 129.8% from the stock's current price. View analysts price targets for ANGO or view top-rated stocks among Wall Street analysts. How have ANGO shares performed in 2023? AngioDynamics' stock was trading at $13.77 at the beginning of the year. Since then, ANGO stock has decreased by 9.9% and is now trading at $12.40. View the best growth stocks for 2023 here. When is AngioDynamics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 30th 2023. View our ANGO earnings forecast. How can I listen to AngioDynamics' earnings call? AngioDynamics will be holding an earnings conference call on Thursday, March 30th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 412-317-6671 with passcode "13737051". How were AngioDynamics' earnings last quarter? AngioDynamics, Inc. (NASDAQ:ANGO) posted its quarterly earnings data on Thursday, January, 5th. The medical instruments supplier reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.01) by $0.02. The medical instruments supplier earned $85.43 million during the quarter, compared to the consensus estimate of $84.05 million. AngioDynamics had a negative net margin of 9.98% and a negative trailing twelve-month return on equity of 0.14%. What ETFs hold AngioDynamics' stock? ETFs with the largest weight of AngioDynamics (NASDAQ:ANGO) stock in their portfolio include SPDR S&P Health Care Equipment ETF (XHE), Invesco Raymond James SB-1 Equity ETF (RYJ), Invesco S&P SmallCap Health Care ETF (PSCH), Invesco Nasdaq Future Gen 200 ETF (QQQS), First Trust Active Factor Small Cap ETF (AFSM), SPDR S&P Kensho New Economies Composite ETF (KOMP), Global X Aging Population ETF (AGNG) and Principal Healthcare Innovators ETF (BTEC). What guidance has AngioDynamics issued on next quarter's earnings? AngioDynamics updated its FY23 earnings guidance on Thursday, January, 5th. The company provided earnings per share guidance of $0.01-0.06 for the period, compared to the consensus estimate of $0.01. The company issued revenue guidance of $342-346 million, compared to the consensus revenue estimate of $342.48 million. What is James C. Clemmer's approval rating as AngioDynamics' CEO? 34 employees have rated AngioDynamics Chief Executive Officer James C. Clemmer on Glassdoor.com. James C. Clemmer has an approval rating of 50% among the company's employees. This puts James C. Clemmer in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 47.0% of employees surveyed would recommend working at AngioDynamics to a friend. What other stocks do shareholders of AngioDynamics own? Based on aggregate information from My MarketBeat watchlists, some companies that other AngioDynamics investors own include General Electric (GE), Intel (INTC), Oasis Petroleum (OAS), Advanced Micro Devices (AMD), Freeport-McMoRan (FCX), Amicus Therapeutics (FOLD), Rigel Pharmaceuticals (RIGL), Accuray (ARAY), Celldex Therapeutics (CLDX) and Chimerix (CMRX). What is AngioDynamics' stock symbol? AngioDynamics trades on the NASDAQ under the ticker symbol "ANGO." Who are AngioDynamics' major shareholders? AngioDynamics' stock is owned by a number of institutional and retail investors. Top institutional investors include Victory Capital Management Inc. (10.89%), Victory Capital Management Inc. (10.89%), Victory Capital Management Inc. (10.89%), Dimensional Fund Advisors LP (6.87%), Millennium Management LLC (4.99%) and Systematic Financial Management LP (3.25%). Insiders that own company stock include Chad Thomas Campbell, Dave Helsel, James C Clemmer, James C Clemmer, Scott Centea, Stephen A Trowbridge and Wesley Johnson. View institutional ownership trends. How do I buy shares of AngioDynamics? Shares of ANGO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is AngioDynamics' stock price today? One share of ANGO stock can currently be purchased for approximately $12.40. How much money does AngioDynamics make? AngioDynamics (NASDAQ:ANGO) has a market capitalization of $485.21 million and generates $316.22 million in revenue each year. The medical instruments supplier earns $-26,550,000.00 in net income (profit) each year or ($0.83) on an earnings per share basis. How many employees does AngioDynamics have? The company employs 800 workers across the globe. Does AngioDynamics have any subsidiaries? The following companies are subsidiares of AngioDynamics: AngioDynamics Canada Inc., AngioDynamics France SARL, AngioDynamics Medical Brasil Participacoes Ltda., AngioDynamics Netherlands B. V., AngioDynamics UK Limited, AngioDynamics VA LLC, Clinical Devices, Eximo Medical Ltd., FlowMedica, NM Holding Company Inc., Navilyst Medical Holdings Inc., Navilyst Medical Inc., Oncovionic, RITA Medical Systems, RITA Medical Systems LLC, RadiaDyne LLC, and Vortex Medical.Read More How can I contact AngioDynamics? AngioDynamics' mailing address is 14 PLAZA DRIVE, LATHAM NY, 12110. The official website for the company is www.angiodynamics.com. The medical instruments supplier can be reached via phone at (518) 795-1400, via email at mpolyviou@evcgroup.com, or via fax at 518-795-1401. This page (NASDAQ:ANGO) was last updated on 3/29/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.